Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Cantor Fitzgerald to Strong-Buy Rating

Cantor Fitzgerald upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS - Free Report) to a strong-buy rating in a report released on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics' FY2025 earnings at ($0.54) EPS.

A number of other research analysts have also recently commented on the stock. Leerink Partners upgraded shares of Aclaris Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. Jefferies Financial Group upgraded Aclaris Therapeutics from a "hold" rating to a "buy" rating and raised their target price for the stock from $2.00 to $7.00 in a research report on Tuesday, November 19th. BTIG Research upgraded Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $8.00 price target on the stock in a research report on Tuesday, November 19th. Piper Sandler raised Aclaris Therapeutics from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $3.00 to $13.00 in a report on Monday, November 18th. Finally, Leerink Partnrs raised shares of Aclaris Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $11.67.

Remove Ads

Aclaris Therapeutics Stock Up 0.5 %

Aclaris Therapeutics stock traded up $0.01 on Tuesday, hitting $1.83. The company's stock had a trading volume of 1,197,748 shares, compared to its average volume of 768,692. The company has a fifty day moving average price of $2.34 and a 200-day moving average price of $2.18. The firm has a market cap of $197.49 million, a P/E ratio of -3.52 and a beta of 0.48. Aclaris Therapeutics has a one year low of $0.95 and a one year high of $5.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BML Capital Management LLC lifted its position in shares of Aclaris Therapeutics by 9.7% in the third quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company's stock worth $16,388,000 after purchasing an additional 1,261,866 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Aclaris Therapeutics by 187.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company's stock worth $382,000 after purchasing an additional 216,826 shares during the last quarter. Stonepine Capital Management LLC increased its position in shares of Aclaris Therapeutics by 27.6% during the 3rd quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company's stock worth $2,828,000 after purchasing an additional 531,427 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Aclaris Therapeutics in the 3rd quarter valued at about $1,053,000. Finally, Geode Capital Management LLC increased its position in Aclaris Therapeutics by 9.3% during the third quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company's stock worth $974,000 after buying an additional 72,309 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company's stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.